Literature DB >> 19933218

Pharmacological and environmental factors in primary angle-closure glaucoma.

Ian Subak-Sharpe1, Sancy Low, Winifred Nolan, Paul J Foster.   

Abstract

INTRODUCTION OR
BACKGROUND: A large number of drug classes have now been reported to provoke angle closure in high-risk individuals. The mechanism of action can be generalized into three main categories: sympathomimetic, parasympatholytic and idiosyndratic reactions. SOURCES OF DATA: This review of the ophthalmic literature provides a clinical summary of primary angle-closure glaucoma (PACG) and its management. AREAS OF AGREEMENT: External stimuli (pharmacological and environmental) may induce acute, and more often, asymptomatic angle closure, which carries a significant risk of glaucoma. GROWING POINTS: Whenever in doubt, patients at risk of PACG who are starting on drug therapy known to provoke angle closure or aggravate the condition should be referred for detailed gonioscopic examination of the anterior chamber by an ophthalmologist. AREAS FOR DEVELOPING RESEARCH: The use of new imaging methods such as anterior segment optical coherence tomography to assess the presence or risk of angle closure is gaining popularity, and may offer a more rapid method of identifying people who are at risk of sight loss from angle-closure glaucoma precipitated by non-ophthalmological medication.

Entities:  

Mesh:

Year:  2009        PMID: 19933218     DOI: 10.1093/bmb/ldp042

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  12 in total

Review 1.  The genetic mechanisms of primary angle closure glaucoma.

Authors:  D F Ahram; W L Alward; M H Kuehn
Journal:  Eye (Lond)       Date:  2015-07-24       Impact factor: 3.775

2.  Urologic medications and ophthalmologic side effects: a review.

Authors:  Johan Gani; Nathan Perlis; Sidney B Radomski
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

Review 3.  Bilateral acute angle closure glaucoma and myopic shift by topiramate-induced ciliochoroidal effusion: case report and literature review.

Authors:  Yu-Wen Lan; Jui-Wen Hsieh
Journal:  Int Ophthalmol       Date:  2017-10-24       Impact factor: 2.031

Review 4.  Has the EAGLE landed for the use of clear lens extraction in angle-closure glaucoma? And how should primary angle-closure suspects be treated?

Authors:  Luke Tanner; Gus Gazzard; Winifred P Nolan; Paul J Foster
Journal:  Eye (Lond)       Date:  2019-10-24       Impact factor: 3.775

Review 5.  Psychotropic Drug-Induced Glaucoma: A Practical Guide to Diagnosis and Management.

Authors:  Neeranjali S Jain; Claire W Ruan; Shanil R Dhanji; Richard J Symes
Journal:  CNS Drugs       Date:  2021-02-19       Impact factor: 5.749

Review 6.  Updates on Genes and Genetic Mechanisms Implicated in Primary Angle-Closure Glaucoma.

Authors:  Altaf A Kondkar
Journal:  Appl Clin Genet       Date:  2021-03-09

7.  Bilateral Transient Myopia with Sulfasalazine Treatment.

Authors:  Tal Paz; Daniel Rappoport; Assaf Hilely; Hana Leiba
Journal:  Clin Med Insights Case Rep       Date:  2019-06-18

8.  Acute Primary Angle Closure Caused by Plateau Iris After Ritodrine Use in a Primigravid Woman Successfully Treated With Clear-Lens Extraction: A Case Report.

Authors:  Sayaka Yoshida; Masaaki Yoshida; Noriko Himori; Shiho Kunimatsu-Sanuki; Toru Nakazawa
Journal:  Cureus       Date:  2022-02-08

9.  Genotype-phenotype analysis of SNPs associated with primary angle closure glaucoma (rs1015213, rs3753841 and rs11024102) and ocular biometry in the EPIC-Norfolk Eye Study.

Authors:  Alexander C Day; Robert Luben; Anthony P Khawaja; Sancy Low; Shabina Hayat; Nichola Dalzell; Nicholas J Wareham; Kay-Tee Khaw; Paul J Foster
Journal:  Br J Ophthalmol       Date:  2013-03-15       Impact factor: 4.638

10.  Bilateral acute myopia and angle closure glaucoma induced by Ma-huang (Ephedra): A case report.

Authors:  So Jung Ryu; Yong Un Shin; Min Ho Kang; Hee Yoon Cho; Mincheol Seong
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.